Standard Biotools Stock Performance
| LAB Stock | USD 1.47 0.03 2.00% |
On a scale of 0 to 100, Standard Biotools holds a performance score of 5. The entity has a beta of 1.39, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Standard Biotools will likely underperform. Please check Standard Biotools' jensen alpha, maximum drawdown, and the relationship between the coefficient of variation and sortino ratio , to make a quick decision on whether Standard Biotools' existing price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Standard Biotools are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Standard Biotools sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | What dividend safety rating applies to Standard BioTools Inc. stock - July 2025 Sector Moves Growth Focused Stock Reports - newser.com | 10/01/2025 |
2 | Acquisition by Casdin Partners Master Fund, L.p. of 100000 shares of Standard Biotools at 1.2892 subject to Rule 16b-3 | 10/15/2025 |
3 | Standard BioTools Issues Quarterly Earnings Results | 11/05/2025 |
4 | Acquisition by Casdin Partners Master Fund, L.p. of 225000 shares of Standard Biotools at 1.1234 subject to Rule 16b-3 | 11/07/2025 |
5 | Acquisition by Casdin Partners Master Fund, L.p. of 375000 shares of Standard Biotools at 1.1889 subject to Rule 16b-3 | 11/12/2025 |
6 | Acquisition by Casdin Partners Master Fund, L.p. of 250000 shares of Standard Biotools at 1.2392 subject to Rule 16b-3 | 11/14/2025 |
7 | Standard BioTools Director Casdin Partners Master Fund, L Acquires 250,000 Shares | 11/18/2025 |
8 | Acquisition by Casdin Partners Master Fund, L.p. of 350000 shares of Standard Biotools at 1.2826 subject to Rule 16b-3 | 11/19/2025 |
9 | Acquisition by Casdin Partners Master Fund, L.p. of 450000 shares of Standard Biotools at 1.3028 subject to Rule 16b-3 | 11/20/2025 |
10 | Standard BioTools Director Acquires 585,000.00 in Stock | 11/21/2025 |
11 | Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4325 subject to Rule 16b-3 | 11/24/2025 |
12 | Acquisition by Casdin Partners Master Fund, L.p. of 7550000 shares of Standard Biotools at 1.3031 subject to Rule 16b-3 | 11/25/2025 |
13 | Acquisition by Casdin Partners Master Fund, L.p. of 125000 shares of Standard Biotools at 1.4201 subject to Rule 16b-3 | 12/02/2025 |
14 | Hyundai Motor, Kias Robotics LAB and DEEPX Begin Commercialization for Next-Generation On-Device AI Robot Platform | 12/03/2025 |
15 | Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4468 subject to Rule 16b-3 | 12/04/2025 |
16 | Single Cell Sample Preparation Market by Application, Country and Region, 2025-2035 - Demand Escalates for Single-Cell Research Tools Amid Rising Chronic Diseas... | 12/10/2025 |
17 | Standard BioTools Stock Price Down 3.9 percent - Time to Sell - MarketBeat | 12/19/2025 |
| Begin Period Cash Flow | 52.5 M | |
| Total Cashflows From Investing Activities | 363.2 M |
Standard Biotools Relative Risk vs. Return Landscape
If you would invest 130.00 in Standard Biotools on September 26, 2025 and sell it today you would earn a total of 17.00 from holding Standard Biotools or generate 13.08% return on investment over 90 days. Standard Biotools is generating 0.2617% of daily returns assuming volatility of 3.6535% on return distribution over 90 days investment horizon. In other words, 32% of stocks are less volatile than Standard, and above 95% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Standard Biotools Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Standard Biotools' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Standard Biotools, and traders can use it to determine the average amount a Standard Biotools' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0716
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LAB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Standard Biotools is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Standard Biotools by adding it to a well-diversified portfolio.
Standard Biotools Fundamentals Growth
Standard Stock prices reflect investors' perceptions of the future prospects and financial health of Standard Biotools, and Standard Biotools fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Standard Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.76) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 478.56 M | ||||
| Shares Outstanding | 384.57 M | ||||
| Price To Earning | (2.52) X | ||||
| Price To Book | 1.62 X | ||||
| Price To Sales | 3.39 X | ||||
| Revenue | 174.43 M | ||||
| Gross Profit | 81.9 M | ||||
| EBITDA | (118.14 M) | ||||
| Net Income | (138.88 M) | ||||
| Cash And Equivalents | 81.31 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 33 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 5.87 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (143.45 M) | ||||
| Earnings Per Share | (0.39) X | ||||
| Market Capitalization | 574.93 M | ||||
| Total Asset | 612.34 M | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | 309.99 M | ||||
About Standard Biotools Performance
By analyzing Standard Biotools' fundamental ratios, stakeholders can gain valuable insights into Standard Biotools' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Standard Biotools has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Standard Biotools has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 164.90 | 196.27 | |
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.29) | (0.31) |
Things to note about Standard Biotools performance evaluation
Checking the ongoing alerts about Standard Biotools for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Standard Biotools help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Standard Biotools may become a speculative penny stock | |
| Standard Biotools had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 174.43 M. Reported Net Loss for the year was (138.88 M) with profit before taxes, overhead, and interest of 81.9 M. | |
| Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Standard Biotools has a poor financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Standard BioTools Stock Price Down 3.9 percent - Time to Sell - MarketBeat |
- Analyzing Standard Biotools' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Standard Biotools' stock is overvalued or undervalued compared to its peers.
- Examining Standard Biotools' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Standard Biotools' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Standard Biotools' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Standard Biotools' stock. These opinions can provide insight into Standard Biotools' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |